Deep Brain Stimulation (DBS) is an FDA-approved procedure, a two-part surgery that involves implanting a device that sends ...

The Phase III DIAMOND trial met both its primary and secondary endpoints of reducing tics in both children and adult patients ...

Results from a Phase III registrational study suggest that ecopipam has potential as a first-in-class dopamine-1 receptor ...

Ecopipam showed statistical significance in treating Tourette syndrome versus a placebo for both its primary efficacy ...

In the Phase III trial, 41.9% of pediatric Tourette syndrome patients relapsed after ecopipam treatment, as compared with ...

The next episode of “Baylen Out Loud” is called “You Don’t Have to Stare Into My Soul.” “Baylen Out Loud” airs at 9 p.m.

Wake Forest University School of Medicine and Atrium Health Wake Forest Baptist Medical Center have been recognized by the ...

During the double-blind withdrawal period, 41.9% of ecopipam-treated patients relapsed compared with 68.1% of placebo-treated patients. Topline data were announced from a phase 3 trial evaluating ...

Chicago, USA-based Emalex Biosciences announced positive top-line data from its Phase III registrational study of ecopipam, a ...

Since Baylen Out Loud premiered on TLC in January 2025, Tourette syndrome advocate Baylen Dupree has gained even more social ...